Milroy J Samuel MD
Addiction Medicine
Complete Healthcare Addiction & Gynecology
Join to View Full Profile
5910 Cleveland AveColumbus, OH 43231
Phone+1 614-882-4343
Fax+1 614-882-4664
Dr. Samuel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University/Mt Carmel HospitalResidency, Obstetrics and Gynecology, 1997 - 2001
Meharry Medical CollegeClass of 1997
Certifications & Licensure
FL State Medical License 2001 - 2027
OH State Medical License 1998 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Preventive Medicine Addiction Medicine
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Most Compassionate Doctor American Registry
- Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Clinical Trials
- HOME Study: Hysteroscopic Office Myomectomy Evaluation Start of enrollment: 2010 Jun 01
- Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies Start of enrollment: 2012 Mar 01
- A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents Start of enrollment: 2014 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsA Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescen...Steven E. Chavoustie, Janet K Gersten, Milroy J Samuel, Jane R. Schwebke
Journal of Women's Health. 2018-01-11 - Abnormal human chorionic gonadotropin levels and normal pregnancy outcomes in the ovarian hyperstimulation syndrome.Milroy J Samuel, Clemens M Grosskinsky
The Journal of Reproductive Medicine. 2004-01-01
Authored Content
- A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 G for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial VaginosisJanuary 2018
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
